AAAAAA
Results:
1-22
|
Results: 22
Authors:
Jirouskova, M
Smyth, SS
Kudryk, B
Coller, BS
Citation: M. Jirouskova et al., A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis, THROMB HAEM, 86(4), 2001, pp. 1047-1056
Authors:
Coller, BS
Citation: Bs. Coller, Anti-GPIIb/IIIa drugs: Current strategies and future directions, THROMB HAEM, 86(1), 2001, pp. 427-443
Authors:
Smyth, SS
Reis, ED
Zhang, W
Fallon, JT
Gordon, RE
Coller, BS
Citation: Ss. Smyth et al., beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury - Correlation with leukocyte recruitment to adherent platelets 1 hour after injury, CIRCULATION, 103(20), 2001, pp. 2501-2507
Authors:
Zhang, ZG
Zhang, L
Tsang, W
Goussev, A
Powers, C
Ho, KL
Morris, D
Smyth, SS
Coller, BS
Chopp, M
Citation: Zg. Zhang et al., Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion, BRAIN RES, 912(2), 2001, pp. 181-194
Authors:
Smyth, SS
Reis, ED
Vaananen, H
Zhang, W
Coller, BS
Citation: Ss. Smyth et al., Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms, BLOOD, 98(4), 2001, pp. 1055-1062
Authors:
Reis, ED
Smyth, SS
Coller, BS
Citation: Ed. Reis et al., Mouse model of transluminal femoral artery injury, CONTEMP CAR, 2001, pp. 103-113
Authors:
Nutter, DO
Bond, JS
Coller, BS
D'Alessandri, RM
Gewertz, BL
Nora, LM
Perkins, JP
Shomaker, TS
Watson, RT
Citation: Do. Nutter et al., Measuring faculty effort and contributions in medical education, ACAD MED, 75(2), 2000, pp. 200-207
Authors:
Smyth, SS
Tsakiris, DA
Scudder, LE
Coller, BS
Citation: Ss. Smyth et al., Structure and function of murine alpha IIb beta 3 (GPIIb/IIIa): Studies using monoclonal antibodies and beta 3-null mice, THROMB HAEM, 84(6), 2000, pp. 1103-1108
Authors:
Steinhubl, SR
Kottke-Marchant, K
Moliterno, DJ
Rosenthal, M
Topol, EJ
Lincoff, AM
Coller, BS
Citation: Sr. Steinhubl et al., Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients undergoing percutaneous coronary intervention - Response, CIRCULATION, 102(25), 2000, pp. E186-E186
Authors:
Kaul, DK
Tsai, HM
Liu, XD
Nakada, MT
Nagel, RL
Coller, BS
Citation: Dk. Kaul et al., Monoclonal antibodies to alpha V beta 3 (7E3 and LM609) inhibit sickle redblood cell-endothelium interactions induced by platelet-activating factor, BLOOD, 95(2), 2000, pp. 368-374
Authors:
Basani, RB
French, DL
Vilaire, G
Brown, DL
Chen, FP
Coller, BS
Derrick, JM
Gartner, TK
Bennett, JS
Poncz, M
Citation: Rb. Basani et al., A naturally occurring mutation near the amino terminus of alpha IIb defines a new region involved in ligand binding to alpha IIb beta 3, BLOOD, 95(1), 2000, pp. 180-188
Authors:
Hayes, R
Chesebro, JH
Fuster, V
Dongas, G
Fallon, JT
Sharma, SK
Coller, BS
Badimon, L
Marmur, JD
Badimon, JJ
Citation: R. Hayes et al., Antithrombotic effects of abciximab, AM J CARD, 85(10), 2000, pp. 1167-1172
Authors:
Coller, BS
Citation: Bs. Coller, Binding of Abciximab to a alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leucocyte interactions (vol 82, pg 326, 1999), THROMB HAEM, 82(5), 1999, pp. XII-XII
Authors:
Coller, BS
Citation: Bs. Coller, Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leukocyte interactions, THROMB HAEM, 82(2), 1999, pp. 326-336
Authors:
Tsakiris, DA
Scudder, L
Hodivala-Dilke, K
Hynes, RO
Coller, BS
Citation: Da. Tsakiris et al., Hemostasis in the mouse (Mus musculus): A review, THROMB HAEM, 81(2), 1999, pp. 177-188
Authors:
Hodivala-Dilke, KM
McHugh, KP
Tsakiris, DA
Rayburn, H
Crowley, D
Ullman-Cullere, M
Ross, FP
Coller, BS
Teitelbaum, S
Hynes, RO
Citation: Km. Hodivala-dilke et al., beta 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival, J CLIN INV, 103(2), 1999, pp. 229-238
Authors:
Smith, JW
Steinhubl, SR
Lincoff, AM
Coleman, JC
Lee, TT
Hillman, RS
Coller, BS
Citation: Jw. Smith et al., Rapid platelet-function assay - An automated and quantitative cartridge-based method, CIRCULATION, 99(5), 1999, pp. 620-625
Authors:
Steinhubl, SR
Kottke-Marchant, K
Moliterno, DJ
Rosenthal, ML
Godfrey, NK
Coller, BS
Topol, EJ
Lincoff, AM
Citation: Sr. Steinhubl et al., Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention, CIRCULATION, 100(19), 1999, pp. 1977-1982
Authors:
Beguin, S
Kumar, R
Keularts, I
Seligsohn, U
Coller, BS
Hemker, HC
Citation: S. Beguin et al., Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor, BLOOD, 93(2), 1999, pp. 564-570
Authors:
Lengweiler, S
Smyth, SS
Jirouskova, M
Scudder, LE
Park, H
Moran, T
Coller, BS
Citation: S. Lengweiler et al., Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alpha IIb beta 3) and other proteins from hamster-mouse interspecies hybridomas, BIOC BIOP R, 262(1), 1999, pp. 167-173
Authors:
Coller, BS
Citation: Bs. Coller, Potential non-glycoprotein IIb IIIa effects of abciximab, AM HEART J, 138(1), 1999, pp. S1-S5
Authors:
Coller, BS
Citation: Bs. Coller, Glycoprotein IIb/IIIa antagonists: Development of abciximab and pharmacology of select agents, CONTEMP CAR, 2, 1999, pp. 67-89
Risultati:
1-22
|